- Home
- MFM vs HELP Comparison
MFM vs HELP Comparison
Compare MFM & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MFM | HELP |
|---|---|---|
| Founded | 1986 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.3M | 233.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MFM | HELP |
|---|---|---|
| Price | $5.60 | $6.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 276.8K | ★ 1.3M |
| Earning Date | 01-01-0001 | 07-01-2026 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $187.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.03 | $3.76 |
| 52 Week High | $5.67 | $8.55 |
Technical Indicators
Market Signals| Indicator | MFM | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 71.38 | 66.28 |
| Support Level | $5.34 | $5.76 |
| Resistance Level | $5.66 | $6.26 |
| Average True Range (ATR) | 0.06 | 0.44 |
| MACD | 0.01 | 0.22 |
| Stochastic Oscillator | 72.73 | 73.11 |
Price Performance
Historical ComparisonAbout MFM MFS Municipal Income Trust
MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but it may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.
About HELP Cybin Inc. Common Stock
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.